Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/24/2023* -- Results Q4 2022 -- -0.83 --
11/04/2022 -- Results Q3 2022 -0.92 -0.73 -26.51%
08/05/2022 -- Results Q2 2022 -0.77 -0.86 10.96%
05/06/2022 -- Results Q1 2022 -0.74 -0.84 11.74%
02/25/2022 -- Results Q4 2021 -0.93 -0.81 -15.06%
11/12/2021 -- Results Q3 2021 -0.70 -0.91 22.80%
08/13/2021 -- Results Q2 2021 -0.83 -0.71 -17.62%
05/13/2021 -- Results Q1 2021 -0.43 -0.94 54.06%
*Estimated Date/Time

Earnings

Next Report Date 02/24/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/04/2022
Beat/Miss Upgrade
Return Since 27.99%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
URL https://www.akerotx.com
Investor Relations URL https://ir.akerotx.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
--
--
--
--
16.24%
-18.02%
159.1%
-10.13%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
6.11%
20.94%
516.0%
22.80%
-19.17%
22.02%
-23.77%
242.5%
-0.26%
-57.14%
416.7%
-42.65%
-60.98%
-7.58%
-18.72%
218.8%
0.33%
-27.25%
-46.23%
72.53%
22.95%
-80.07%
-34.05%
-24.06%
48.75%
6.64%
175.2%
-43.60%
-44.14%
-28.92%
-61.70%
110.4%
11.88%
As of January 27, 2023.

Profile

Edit
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
URL https://www.akerotx.com
Investor Relations URL https://ir.akerotx.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
PTH 5.127M USD 2.36%
XBI 80.59M USD 1.00%
DWAS 3.592M USD 0.86%
LABU 7.079M USD 0.64%
IWC 3.578M USD 0.37%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter AKRO Tweets